Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

FDA Expands Evolut Indication to Include Redo TAVI

News Daily News

FDA Expands Evolut Indications to Include Redo TAVI

Yael L. Maxwell

August 29, 2025

News Daily News

Symplicity Spyral Approved: FDA Clears Second Renal Denervation System

Todd Neale

November 20, 2023

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

News Daily News

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

Shelley Wood

June 01, 2020

News Daily News

FDA Clears Dapagliflozin for Heart Failure With Reduced Ejection Fraction

Shelley Wood

May 06, 2020

News Daily News

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

Shelley Wood

February 26, 2020

News Conference News STS 2020

TAVR Tussle at US Surgery Meeting Threatens to Widen Surgeon-Cardiologist Wedge

Yael L. Maxwell

January 29, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

‘The Bleeding Edge’ Documentary, Tackling Medical Device Regulation, Spurs Diverse Cardiology Reactions

Yael L. Maxwell

August 17, 2018

News Daily News

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Michael O'Riordan

July 10, 2017

News Daily News

FDA Approves Amplatzer PFO Occluder for Prevention of Recurrent Stroke

Yael L. Maxwell

October 28, 2016

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

Advertisement

FDA Expands Evolut Indications to Include Redo TAVI

Symplicity Spyral Approved: FDA Clears Second Renal Denervation System

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

FDA Approves Empagliflozin for Treatment of HFpEF

British Medical Groups Express Concern About Inclisiran Rollout

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

FDA Clears Dapagliflozin for Heart Failure With Reduced Ejection Fraction

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

TAVR Tussle at US Surgery Meeting Threatens to Widen Surgeon-Cardiologist Wedge

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

‘The Bleeding Edge’ Documentary, Tackling Medical Device Regulation, Spurs Diverse Cardiology Reactions

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

FDA Approves Amplatzer PFO Occluder for Prevention of Recurrent Stroke

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content